JP2014530239A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530239A5 JP2014530239A5 JP2014535877A JP2014535877A JP2014530239A5 JP 2014530239 A5 JP2014530239 A5 JP 2014530239A5 JP 2014535877 A JP2014535877 A JP 2014535877A JP 2014535877 A JP2014535877 A JP 2014535877A JP 2014530239 A5 JP2014530239 A5 JP 2014530239A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- sema4d
- binding molecule
- subject
- brain barrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010056102 CD100 antigen Proteins 0.000 claims description 54
- 102100027744 Semaphorin-4D Human genes 0.000 claims description 54
- 230000008499 blood brain barrier function Effects 0.000 claims description 20
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 20
- 230000035699 permeability Effects 0.000 claims description 19
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 16
- 102100034384 Plexin-B1 Human genes 0.000 claims description 13
- 101710100559 Plexin-B1 Proteins 0.000 claims description 13
- 239000003112 inhibitor Substances 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 230000003993 interaction Effects 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 8
- 206010048962 Brain oedema Diseases 0.000 claims description 4
- 102000004057 Claudin-5 Human genes 0.000 claims description 4
- 108090000582 Claudin-5 Proteins 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 208000006752 brain edema Diseases 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 150000003384 small molecules Chemical class 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 201000009906 Meningitis Diseases 0.000 claims description 2
- 230000004888 barrier function Effects 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 108020003175 receptors Proteins 0.000 claims 5
- 210000002889 endothelial cell Anatomy 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 210000001130 astrocyte Anatomy 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000018109 developmental process Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 102000002022 plexin Human genes 0.000 claims 2
- 108050009312 plexin Proteins 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 230000003844 B-cell-activation Effects 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 208000031124 Dementia Alzheimer type Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012305 Demyelination Diseases 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000005875 antibody response Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 230000008859 change Effects 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 230000004041 dendritic cell maturation Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 230000010595 endothelial cell migration Effects 0.000 claims 1
- 210000003038 endothelium Anatomy 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 230000016784 immunoglobulin production Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 210000004248 oligodendroglia Anatomy 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000002269 spontaneous effect Effects 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 23
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161545809P | 2011-10-11 | 2011-10-11 | |
| US61/545,809 | 2011-10-11 | ||
| US201161555726P | 2011-11-04 | 2011-11-04 | |
| US61/555,726 | 2011-11-04 | ||
| US201261593641P | 2012-02-01 | 2012-02-01 | |
| US61/593,641 | 2012-02-01 | ||
| PCT/US2012/059757 WO2013055922A1 (en) | 2011-10-11 | 2012-10-11 | Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017129377A Division JP2017193569A (ja) | 2011-10-11 | 2017-06-30 | 血液脳関門透過性の調節のためのセマフォリン−４ｄ結合分子の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530239A JP2014530239A (ja) | 2014-11-17 |
| JP2014530239A5 true JP2014530239A5 (enExample) | 2015-12-03 |
| JP6395606B2 JP6395606B2 (ja) | 2018-09-26 |
Family
ID=48082436
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014535877A Active JP6395606B2 (ja) | 2011-10-11 | 2012-10-11 | 血液脳関門透過性の調節のためのセマフォリン−４ｄ結合分子の使用 |
| JP2017129377A Pending JP2017193569A (ja) | 2011-10-11 | 2017-06-30 | 血液脳関門透過性の調節のためのセマフォリン−４ｄ結合分子の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017129377A Pending JP2017193569A (ja) | 2011-10-11 | 2017-06-30 | 血液脳関門透過性の調節のためのセマフォリン−４ｄ結合分子の使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20130095118A1 (enExample) |
| EP (1) | EP2766093B1 (enExample) |
| JP (2) | JP6395606B2 (enExample) |
| KR (1) | KR101999872B1 (enExample) |
| CN (2) | CN104168956A (enExample) |
| AU (1) | AU2012322721B2 (enExample) |
| BR (1) | BR112014008885B1 (enExample) |
| CA (1) | CA2851805C (enExample) |
| DK (1) | DK2766093T3 (enExample) |
| EA (1) | EA029023B1 (enExample) |
| ES (1) | ES2669209T3 (enExample) |
| IL (1) | IL232072B (enExample) |
| MX (1) | MX353550B (enExample) |
| PT (1) | PT2766093T (enExample) |
| SG (1) | SG11201401458UA (enExample) |
| WO (1) | WO2013055922A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2427212T3 (enExample) | 2009-05-08 | 2018-01-20 | ||
| US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| BR112015032690B1 (pt) | 2013-06-25 | 2020-03-10 | Vaccinex, Inc. | Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase |
| NZ630881A (en) * | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) * | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| EP3881857B1 (en) | 2016-02-18 | 2025-04-16 | The Penn State Research Foundation | Generating gabaergic neurons in brains |
| BR112018071686A2 (pt) | 2016-04-22 | 2019-02-19 | Vaccinex, Inc. | exibição de proteínas integrais de membrana em vírions extracelulares envelopados de poxvírus |
| WO2018026715A1 (en) | 2016-08-02 | 2018-02-08 | Vaccinex, Inc. | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
| RU2753441C2 (ru) * | 2016-09-13 | 2021-08-16 | Ангиокрин Биосайенс, Инк. | Гематоэнцефалический барьер, содержащий сконструированные эндотелиальные клетки |
| WO2018156509A1 (en) * | 2017-02-22 | 2018-08-30 | Vaccinex, Inc. | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
| CN110636858B (zh) | 2017-05-05 | 2024-03-19 | 瓦西尼斯公司 | 人抗脑信号蛋白4d抗体 |
| KR20230007557A (ko) * | 2017-09-22 | 2023-01-12 | 카이트 파마 인코포레이티드 | 키메라 폴리펩티드 및 그의 용도 |
| EP3746109A4 (en) * | 2018-02-02 | 2021-11-03 | The Penn State Research Foundation | METHODS AND MATERIALS FOR TREATING BRAIN INJURY |
| WO2020154374A1 (en) * | 2019-01-22 | 2020-07-30 | Massachusetts Institute Of Technology | In vitro human blood brain barrier |
| TWI859192B (zh) * | 2019-03-29 | 2024-10-21 | 日商中外製藥股份有限公司 | 包含抗il-6受體抗體之bbb功能低下之抑制劑 |
| CN117597360A (zh) * | 2020-06-25 | 2024-02-23 | 瓦西尼斯公司 | 脑信号蛋白-4d结合分子在rett综合征治疗中的应用 |
| EP3973979A1 (en) * | 2020-09-25 | 2022-03-30 | The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth | A tight junction (zonulae occludentes) protein for use in treating or preventing epilepsy |
| CN113456813A (zh) * | 2021-07-26 | 2021-10-01 | 苏州大学 | Semaphorin7A单克隆抗体在制备用于治疗血栓及脑血管疾病药物方面的应用 |
| WO2023012314A1 (en) * | 2021-08-05 | 2023-02-09 | Lifearc | Anti-plexin-b1 antibodies |
| CN114539204B (zh) * | 2022-03-23 | 2023-08-22 | 福建金兰厚普生物科技有限公司 | 己糖激酶抑制剂及其合成方法和应用 |
| JP7747395B2 (ja) * | 2023-03-28 | 2025-10-01 | 株式会社エヌビィー健康研究所 | 抗体、核酸、細胞、及び医薬 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5070192A (en) | 1988-03-23 | 1991-12-03 | The Johns Hopkins University | Cloned human topoisomerase i: cdna expression, and use for autoantibody detection |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US6497872B1 (en) | 1991-07-08 | 2002-12-24 | Neurospheres Holdings Ltd. | Neural transplantation using proliferated multipotent neural stem cells and their progeny |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| US5639856A (en) | 1993-09-13 | 1997-06-17 | The Regents Of The University Of California | Semaphorin gene family |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6576754B2 (en) | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| ES2236634T3 (es) | 1997-04-07 | 2005-07-16 | Genentech, Inc. | Anticuerpos anti-vegf. |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| WO1998046769A1 (en) | 1997-04-11 | 1998-10-22 | Dendreon Corporation | Composition and method for inducing an immune response against tumour-related antigens |
| EP0892047A3 (de) * | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Humanes und murines Semaphorin L |
| US5968829A (en) | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
| US6638501B1 (en) | 1997-09-29 | 2003-10-28 | Neurospheres Holdings Ltd. | Use of multipotent neural stem cell progeny to augment non-neural tissues |
| US5958767A (en) | 1998-08-14 | 1999-09-28 | The Children's Medical Center Corp. | Engraftable human neural stem cells |
| AU776865B2 (en) | 1998-11-10 | 2004-09-23 | University Of Rochester | T cells specific for target antigens and methods and vaccines based thereon |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| JP3787473B2 (ja) | 1999-11-30 | 2006-06-21 | 独立行政法人科学技術振興機構 | セマフォリン受容体 |
| US6635742B1 (en) | 2000-01-25 | 2003-10-21 | Nuvelo, Inc. | Antibodies specific for semaphorin-like polypeptides |
| WO2001046384A2 (en) | 1999-12-23 | 2001-06-28 | Cornell Research Foundation, Inc. | A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells |
| CN1329060A (zh) | 2000-06-19 | 2002-01-02 | 上海博德基因开发有限公司 | 一种新的多肽——人semaphorin蛋白9和编码这种多肽的多核苷酸 |
| IL159177A0 (en) | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US20080219974A1 (en) | 2002-03-01 | 2008-09-11 | Bernett Matthew J | Optimized antibodies that target hm1.24 |
| EP1365018A1 (en) | 2002-05-23 | 2003-11-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | CD100 semaphorin in myelination |
| JP4524181B2 (ja) | 2002-05-30 | 2010-08-11 | マクロジェニクス，インコーポレーテッド | Ｃｄ１６ａ結合タンパク質および免疫障害治療のための使用 |
| US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
| EP1442749A1 (en) * | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| CN1788017B (zh) * | 2003-02-10 | 2013-04-24 | to-BBB控股股份有限公司 | 炎症状态下在血脑屏障中差异表达的核酸 |
| RS20150135A1 (sr) | 2003-05-30 | 2015-08-31 | Genentech Inc. | Tretman sa anti-vegf antitelima |
| CA2882022A1 (en) | 2003-09-11 | 2005-03-24 | Walter Newman | Monoclonal antibodies against hmgb1 |
| JP5042631B2 (ja) | 2003-12-04 | 2012-10-03 | バクシネックス インコーポレーティッド | アポトーシス腫瘍細胞上に露出した細胞内抗原をターゲッティングすることによって腫瘍細胞を死滅させる方法 |
| RU2006124743A (ru) | 2003-12-11 | 2008-01-20 | Дженентек, Инк. (Us) | СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИНГИБИРОВАНИЯ ДИМЕРИЗАЦИИ И АКТИВАЦИИ с-Мет |
| US7476724B2 (en) | 2004-08-05 | 2009-01-13 | Genentech, Inc. | Humanized anti-cmet antibodies |
| US20060147449A1 (en) | 2004-11-15 | 2006-07-06 | Brass Lawrence F | Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses |
| EP1871484A2 (en) | 2005-04-07 | 2008-01-02 | Chiron Corporation | Sema4d in cancer diagnosis, detection and treatment |
| WO2007057395A2 (en) | 2005-11-16 | 2007-05-24 | Novartis Ag | Biomarkers for anti-nogo-a antibody treatment in spinal cord injury |
| JP2007308465A (ja) | 2006-05-15 | 2007-11-29 | Boehringer Ingelheim Internatl Gmbh | 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法 |
| WO2008025020A2 (en) | 2006-08-25 | 2008-02-28 | Seattle Genetics, Inc. | Cd30 binding agents and uses thereof |
| US9382327B2 (en) | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
| US8906367B2 (en) * | 2007-01-05 | 2014-12-09 | University Of Zurich | Method of providing disease-specific binding molecules and targets |
| EP2069404B1 (en) * | 2007-02-14 | 2011-01-05 | Vaccinex, Inc. | Humanized anti-cd100 antibodies |
| EP2112930B1 (en) | 2007-02-21 | 2017-01-11 | Vaccinex, Inc. | Modulation of nkt cell activity with antigen-loaded cdid molecules |
| EP2237792B1 (en) | 2007-12-26 | 2017-05-24 | Vaccinex, Inc. | Anti-c35 antibody combination therapies and methods |
| WO2009089461A1 (en) | 2008-01-10 | 2009-07-16 | Genentech, Inc. | Plexind1 agonists and their use |
| NO2427212T3 (enExample) | 2009-05-08 | 2018-01-20 | ||
| CA3017298C (en) | 2009-05-15 | 2021-09-28 | Irx Therapeutics, Inc. | Compositions comprising primary cell-derived biologics for enhancing immune responses in patients |
| JP5500944B2 (ja) | 2009-10-29 | 2014-05-21 | 三菱電機株式会社 | 加熱調理器 |
| US8834883B2 (en) | 2010-06-14 | 2014-09-16 | Vaccinex, Inc. | Anti-VEGF antibodies and uses thereof |
| AU2011295902B2 (en) | 2010-09-02 | 2014-12-04 | Vaccinex, Inc. | Anti-CXCL13 antibodies and methods of using the same |
| US9447191B2 (en) | 2011-05-13 | 2016-09-20 | National University Corporation Tokyo Medical And Dental University | Osteogenesis promoter |
| US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
| IN2014DN08199A (enExample) | 2012-03-02 | 2015-05-01 | Vaccinex Inc | |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| EP2951204B1 (en) | 2013-01-31 | 2019-05-22 | Vaccinex, Inc. | Methods for increasing immunoglobulin a levels |
| US9371352B2 (en) | 2013-02-08 | 2016-06-21 | Vaccinex, Inc. | Modified glycolipids and methods of making and using the same |
| BR112015032690B1 (pt) | 2013-06-25 | 2020-03-10 | Vaccinex, Inc. | Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| BR112018071686A2 (pt) | 2016-04-22 | 2019-02-19 | Vaccinex, Inc. | exibição de proteínas integrais de membrana em vírions extracelulares envelopados de poxvírus |
| WO2018026715A1 (en) | 2016-08-02 | 2018-02-08 | Vaccinex, Inc. | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
| WO2018156509A1 (en) | 2017-02-22 | 2018-08-30 | Vaccinex, Inc. | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
-
2012
- 2012-10-11 CN CN201280059376.9A patent/CN104168956A/zh active Pending
- 2012-10-11 MX MX2014004457A patent/MX353550B/es active IP Right Grant
- 2012-10-11 ES ES12839601.7T patent/ES2669209T3/es active Active
- 2012-10-11 SG SG11201401458UA patent/SG11201401458UA/en unknown
- 2012-10-11 BR BR112014008885-3A patent/BR112014008885B1/pt active IP Right Grant
- 2012-10-11 CA CA2851805A patent/CA2851805C/en active Active
- 2012-10-11 DK DK12839601.7T patent/DK2766093T3/en active
- 2012-10-11 KR KR1020147012547A patent/KR101999872B1/ko active Active
- 2012-10-11 PT PT128396017T patent/PT2766093T/pt unknown
- 2012-10-11 EP EP12839601.7A patent/EP2766093B1/en active Active
- 2012-10-11 JP JP2014535877A patent/JP6395606B2/ja active Active
- 2012-10-11 EA EA201490768A patent/EA029023B1/ru not_active IP Right Cessation
- 2012-10-11 CN CN201910351743.6A patent/CN110105452A/zh active Pending
- 2012-10-11 AU AU2012322721A patent/AU2012322721B2/en active Active
- 2012-10-11 US US13/649,651 patent/US20130095118A1/en not_active Abandoned
- 2012-10-11 WO PCT/US2012/059757 patent/WO2013055922A1/en not_active Ceased
-
2014
- 2014-04-10 IL IL232072A patent/IL232072B/en active IP Right Grant
-
2017
- 2017-06-30 JP JP2017129377A patent/JP2017193569A/ja active Pending
-
2019
- 2019-06-06 US US16/433,496 patent/US11534488B2/en active Active